<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Biologic Overview
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/biologic-overview" data-history-node-id="2990" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Biologic Overview – Hannah Lomzenski
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p style="margin-top:1px">
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Background
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                "-cept" refers to fusion of a receptor to the Fc part of human immunoglobulin G1 (IgG1)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                "-mab" indicates a monoclonal antibody (mAb)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                "-ximab" indicates a chimeric mAb
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                "-zumab" indicates a humanized mAb
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                "-umab" indicates a fully human mAb
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                “-tinib” indicates a tyrosine kinase inhibitor (TKIs are small molecule inhibitors rather than true biologics)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               ​​​​​​​
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <p align="center" style="margin-top:1px; text-align:center">
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Kinase inhibition
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
         </span>
        </p>
        <table class="TableGrid2" style="border-collapse:collapse; border:none">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Tofacitinib</td>
      <td>Xeljanz</td>
      <td>JAK-1 and JAK-3 inhibitors</td>
      <td>RA, UC, JIA, psoriatic arthritis</td>
      <td>infections, nasopharyngitis, skin rash, GI sx, GU sx; &lt;1% lymphoma</td>
    </tr>
    <tr>
      <td>Baracitinib</td>
      <td>Olumiant</td>
      <td>JAK-1 and JAK-2 inhibitor</td>
      <td>RA; off-label: COVID-19</td>
      <td>infections, URI, nausea, ÝAST/ALT; &lt;1% lymphoma</td>
    </tr>
    <tr>
      <td>Upadacitinib</td>
      <td>Rinvoq</td>
      <td>non-specific JAK inhibitor</td>
      <td>RA</td>
      <td>URI, nausea, neutropenia, ÝAST, ÝCPK</td>
    </tr>
  </tbody>
</table>
        </table>
        <p align="center" style="margin-top:1px; text-align:center">
        </p>
        <p align="center" style="margin-top:1px; text-align:center">
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                IL-1 inhibition
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
         </span>
        </p>
        <table class="TableGrid2" style="border-collapse:collapse; border:none">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Anakinra</td>
      <td>Kineret</td>
      <td>IL-1 receptor antagonist</td>
      <td>IL-1 receptor antagonist deficiency, neonatal multi-system inflammatory Dz, RA; off-label: gout flares, FMF, recurrent pericarditis, HLH</td>
      <td>HA, vomiting, infections, nasopharyngitis, Ab development; in RA: eosinophilia, decreased WBC</td>
    </tr>
    <tr>
      <td>Canakinumab</td>
      <td>Ilaris</td>
      <td>mAb against IL-1β</td>
      <td>cryoporin-associated periodic syndromes (CAPS), FMF, hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare</td>
      <td>weight gain, GI sx, HA, vertigo, serious infections</td>
    </tr>
    <tr>
      <td>Rilonacept</td>
      <td>Arcalyst</td>
      <td>binds to IL-1β (some binding of IL-1α and IL-1 receptor antagonist)</td>
      <td>CAPS, deficiency of IL-1 receptor antagonist</td>
      <td>URI, infections, hypoesthesia, Ab development</td>
    </tr>
  </tbody>
</table>
        </table>
        <p align="center" style="margin-top:1px; text-align:center">
        </p>
       </div>
       <p>
       </p>
       <div class="WordSection2">
        <p align="center" style="margin-top:1px; text-align:center">
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                TNF-inhibition
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
         </span>
        </p>
        <table class="TableGrid2" style="border-collapse:collapse; border:none">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Adalilumab</td>
      <td>Humira</td>
      <td>mAb against TNFα</td>
      <td>RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa</td>
      <td>skin rash, HA, URI, infections, Ý CPK, +ANA titer (12%), Ab development (3-26%)</td>
    </tr>
    <tr>
      <td>Certolizumab</td>
      <td>Cimzia</td>
      <td>humanized mAb Fab fragment against TNFα</td>
      <td>RA, Crohn’s, AS, psoriasis; *approved for use during pregnancy</td>
      <td>skin rash, nausea, URI, infections</td>
    </tr>
    <tr>
      <td>Etanercept</td>
      <td>Enbrel</td>
      <td>tumor necrosis factor receptor linked to Fc portion of IgG1; binds TNF</td>
      <td>RA, AS, psoriasis, JIA</td>
      <td>skin rash, diarrhea, infections, +ANA titer (11%)</td>
    </tr>
    <tr>
      <td>Infliximab</td>
      <td>Remicade</td>
      <td>chimeric mAb against TNFα</td>
      <td>RA, IBD, AS, psoriasis</td>
      <td>abd pain, URI sx, anemia, Ý ALT, Ab development (10-50%), infections</td>
    </tr>
    <tr>
      <td>Golimumab</td>
      <td>Simponi</td>
      <td>mAb against TNFα</td>
      <td>RA, UC, AS, psoriasis, JIA</td>
      <td>URI, infections, Ab development (16-38%), +ANA titer (4-17%)</td>
    </tr>
  </tbody>
</table>
        </table>
        <p align="center" style="margin-top:1px; text-align:center">
        </p>
        <p align="center" style="margin-top:1px; text-align:center">
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                IL-17 inhibition
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
         </span>
        </p>
        <table class="TableGrid2" style="border-collapse:collapse; border:none">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Secukinumab</td>
      <td>Cosentyx</td>
      <td>human IgG1 mAb against IL-17A</td>
      <td>AS, psoriasis</td>
      <td>infections, nasopharyngitis, GI, IBD (&lt;1%)</td>
    </tr>
    <tr>
      <td>Ixekizumab</td>
      <td>Taltz</td>
      <td>human IgG4 mAb against IL-17A</td>
      <td>AS, psoriasis</td>
      <td>neutropenia, Ab development, infections, URI, Crohn’s (&lt;1%)</td>
    </tr>
  </tbody>
</table>
        </table>
        <p style="margin-top:1px">
        </p>
        <p align="center" style="margin-top:1px; text-align:center">
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Costimulation blockade
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
         </span>
        </p>
        <table class="TableGrid2" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Abatacept</td>
      <td>Orencia</td>
      <td>inhibits T-cell activation by binding CD80 and CD86 on APCs, thus blocking the required CD28 ixn between APCs and T cells.</td>
      <td>RA, psoriasis, JIA</td>
      <td>nausea, UTI, HA, infections, URI, Ab development</td>
    </tr>
  </tbody>
</table>
        </table>
        <p style="margin-top:1px">
        </p>
        <p align="center" style="margin-top:1px; text-align:center">
        </p>
       </div>
       <p>
       </p>
       <div class="WordSection3">
        <p align="center" style="margin-top:1px; text-align:center">
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                B-cell depletion and inhibition
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
         </span>
        </p>
        <table class="TableGrid2" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Rituximab</td>
      <td>Rituxan</td>
      <td>mAb against the CD20 antigen on surface of B-lymphocytes</td>
      <td>CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG, neuromyelitis optica)</td>
      <td>HTN, peripheral edema, night sweats, fever, weight gain, angioedema, arthralgias, Ý ALT, infections, hypophosphatemia, hematologic abnormalities</td>
    </tr>
    <tr>
      <td>Belimumab</td>
      <td>Benlysta</td>
      <td>IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes</td>
      <td>lupus nephritis, SLE</td>
      <td>GI sx, hypersensitivity rxn, infections, psychiatric disturbances</td>
    </tr>
  </tbody>
</table>
        </table>
        <p style="margin-top:1px">
        </p>
       </div>
       <p>
       </p>
       <p align="center" style="margin-top:1px; text-align:center">
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              IL-6 inhibition
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <table class="TableGrid2" style="border-collapse:collapse; border:none">
        <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Tocilizumab</td>
      <td>Actemra</td>
      <td>IL-6 receptor antagonist</td>
      <td>cytokine release syndrome, giant cell arteritis, RA, JIA</td>
      <td>Ý serum cholesterol, Ý AST/ALT, infusion rxn, HSV infection (&lt;2%)</td>
    </tr>
    <tr>
      <td>Sarilumab</td>
      <td>Kevzara</td>
      <td>IL-6 receptor antagonist (soluble + membrane-bound)</td>
      <td>RA</td>
      <td>Ý AST/ALT, HSV infection (&lt;2%)</td>
    </tr>
  </tbody>
</table>
       </table>
       <p style="margin-top:1px">
       </p>
       <p align="center" style="margin-top:1px; text-align:center">
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              IL-12/23 inhibition
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <table class="TableGrid2" style="border-collapse:collapse; border:none">
        <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Generic Name</td>
      <td>Brand Name</td>
      <td>Mechanism of Action</td>
      <td>Common Uses</td>
      <td>Common Side Effects</td>
    </tr>
    <tr>
      <td>Ustekinumab</td>
      <td>Stelara</td>
      <td>mAb against IL-12 + IL-23</td>
      <td>IBD, psoriasis</td>
      <td>infections, nasopharyngitis, Ab development, acne vulgaris, GI sx, GU sx</td>
    </tr>
    <tr>
      <td>Guselkumab</td>
      <td>Tremfya</td>
      <td>human IgG1 mAb against IL-23</td>
      <td>psoriasis</td>
      <td>infections, URI, tinea, GI sx</td>
    </tr>
  </tbody>
</table>
       </table>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>